96 related articles for article (PubMed ID: 27875318)
1. 1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study.
Sychev DA; Burashnikova IS; Kazakov RE
Drug Metab Pers Ther; 2016 Dec; 31(4):205-212. PubMed ID: 27875318
[TBL] [Abstract][Full Text] [Related]
2. Relationship of the
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
[TBL] [Abstract][Full Text] [Related]
4. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
5. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
[TBL] [Abstract][Full Text] [Related]
8. [CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations].
Mustafina OE; Tuktarova IA; Karimov DD; Somova Rs; Nasibullin TR
Genetika; 2015 Jan; 51(1):109-19. PubMed ID: 25857198
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant pharmacogenetic markers in Tatars and Balkars.
Abdullaev SP; Mirzaev KB; Burashnikova IS; Shikaleva AA; Kachanova AA; Abdullaev SP; Akmalova KA; Sozaeva ZA; Grishina EA; Sozaeva MS; Rytkin EI; Sychev DA
Mol Biol Rep; 2020 May; 47(5):3377-3387. PubMed ID: 32303955
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
[TBL] [Abstract][Full Text] [Related]
12. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
13. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency].
Gareeva AE; Zakirov DF; Valinurov RG; Khusnutdinova EK
Mol Biol (Mosk); 2013; 47(6):934-41. PubMed ID: 25509855
[TBL] [Abstract][Full Text] [Related]
15. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
[TBL] [Abstract][Full Text] [Related]
16. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
17. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
19. Association of
Parkhomenko AA; Zastrozhin MS; Pozdnyakov SA; Noskov VV; Zaytsev IA; Ivanchenko VA; Denisenko NP; Akmalova KA; Skryabin V; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Oct; 52(4):52-60. PubMed ID: 36339274
[TBL] [Abstract][Full Text] [Related]
20. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
